3,4-二甲基联苯-4-羧酸 | 122294-09-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二甲基联苯-4-羧酸
• 英文名称: 3',4'-dimethyl[1,1'-biphenyl]-4-carboxylic acid
• 英文别名: 3',4'-dimethyl-biphenyl-4-carboxylic acid；4-(3,4-dimethylphenyl)benzoic acid
• CAS: 122294-09-1
• 化学式: C₁₅H₁₄O₂
• 分子量: 226.275
• InChiKey: GFGYCDJAIZGZTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  3,4-二氨基吡啶 、 3,4-二甲基联苯-4-羧酸 在 碳酸氢钠 作用下， 以 水 为溶剂， 反应 2.0h， 以79%的产率得到2-(3',4'-dimethyl-biphenyl-4-yl)-3H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  WO2007/34277

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(3,4-二甲基苯基)苯甲酸甲酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以50%的产率得到3,4-二甲基联苯-4-羧酸
  参考文献：
  名称：

  Biphenylcarboxamide derivatives as antagonists of platelet-activating factor

  摘要：

  A series of N-[4-(3-pyridinyl)butyl]-1,1'-biphenyl-4-carboxamides was prepared, and the compounds were evaluated for platelet-activating factor (PAF) antagonist activity in a binding assay employing washed, whole dog platelets and in vivo for their ability to inhibit PAF-induced bronchoconstriction in the guinea pig. The inclusion of a methyl group in the R configuration on the side-chain carbon adjacent to the carboxamide nitrogen atom of these derivatives resulted in a marked enhancement of potency in the binding assay for compounds unsubstituted in the biphenyl 2-position and, more importantly, in improved oral bioavailability. Previous work with related pyrido[2,1-b]-quinazoline-8-carboxamides suggests that the presence of such an alkyl group improves bioavailability by rendering the resulting compounds resistant to degradation by liver amidases. The most interesting compounds to emerge from this work are (R)-2-bromo-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]-1,1'-bi phe nyl- 4-carboxamide (33) and (R)-2-butyl-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]- 1,1'-biphenyl-4-carboxamide (40) each of which inhibits PAF-induced bronchoconstriction in the guinea pig by greater than 55%. 6 h after an oral dose of 50 mg/kg.

  DOI：

  10.1021/jm00128a025

文献信息

• [EN] ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS<br/>[FR] DERIVES D'ALCANE-DIOLS UTILISES COMME AGENTS THERAPEUTIQUES POUR LE TRAITEMENT DE PATHOLOGIES OSSEUSES
  申请人：UNIV ABERDEEN

  公开号：WO2003037321A1

  公开（公告）日：2003-05-08

  The present invention pertains to certain alkane diol derivatives (including, e.g., mono- and di-esters) of the formula R1-O-A-O-R2, wherein: A is a C¿2-10?alkylene group; R?1¿ is independently a first hydroxy protecting group (e.g., an ester group); and, R2 is independently -H or a second hydroxy protecting group (e.g., an ester group); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrug thereof, which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or conditions associated with inflammation or activation of the immune system.

  本发明涉及某些烷基二醇衍生物（包括但不限于单酯和二酯），其化学式为R1-O-A-O-R2，其中：A是C2-10烷基基团；R1独立地是第一羟基保护基（例如，酯基）；R2独立地是-H或第二羟基保护基（例如，酯基）；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药，它们可以抑制破骨细胞的存活、形成和/或活性；并且/或抑制骨吸收。本发明还涉及包括这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是在体外还是在体内，以抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导或以骨吸收为特征的疾病，例如骨质疏松症、类风湿性关节炎、与癌症相关的骨疾病、帕吉特病等；以及与炎症或免疫系统激活有关的疾病。
• Substituted n-[(pyridyl)alkyl]aryl-carboxamide
  申请人：Hoffmann-La Roche Inc.

  公开号：US04916145A1

  公开（公告）日：1990-04-10

  The invention relates to compounds of the formula ##STR1## wherein *B is ##STR2## Y is O or S, *A is *--(CH.sub.2).sub.n --(X).sub.m --(CH.sub.2).sub.r --, n or r, independently, are integers from 0 to 3, m is an integer from 0 to 1, provided that when m is 1, then n must be at least 1, X is O or S, R.sub.1 and R.sub.4, independently, are hydrogen, lower alkyl, hydroxy or lower alkoxy, provided that when *B is other than ##STR3## at least one of R.sub.1 and R.sub.4, and one of R.sub.6 and R.sub.7 must be hydrogen, R.sub.2 and R.sub.3 are independently hydrogen, lower alkyl, cycloalkyl, halogen, nitro, lower alkoxy, lower alkenyl, lower alkynyl or aryl, R.sub.5 and R.sub.6, independently are hydrogen or lower alkyl, R.sub.7 is hydrogen, lower alkyl, cycloalkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R.sub.6 and R.sub.7 are different, their enantiomers and racemic mixtures thereof, and pharmaceutical acceptable acid addition salts thereof. The compounds of formula I exhibit activity as Platelet Activating Factor (PAF) antagonists and are, therefore, useful as agents for the prevention and treatment of vascular diseases, pulmonary diseases, dermatological disorders, transplant rejection, immunological disorders and inflammatory conditions.

  本发明涉及公式##STR1##的化合物，其中*B是##STR2##，Y是O或S，*A是*--(CH.sub.2).sub.n --(X).sub.m --(CH.sub.2).sub.r --，n或r独立地是0到3的整数，m是0到1的整数，但当m为1时，n必须至少为1，X是O或S，R.sub.1和R.sub.4独立地是氢，低烷基，羟基或低烷氧基，但当*B不是##STR3##时，R.sub.1和R.sub.4中至少有一个，以及R.sub.6和R.sub.7中的一个必须是氢，R.sub.2和R.sub.3独立地是氢，低烷基，环烷基，卤素，硝基，低烷氧基，低烯基，低炔基或芳基，R.sub.5和R.sub.6独立地是氢或低烷基，R.sub.7是氢，低烷基，环烷基或芳基，Het是单环5-或6-成员杂环芳基或含有一个或两个从氮氧和硫中选择的杂原子的双环杂芳基基团，该基团可以被低烷基，卤素或芳基取代，星号表示连接点，当R.sub.6和R.sub.7不同时，它们的对映体和混合物的酰酸盐，以及药物可接受的酸加成盐。公式I的化合物表现为血小板活化因子（PAF）拮抗剂的活性，因此，它们可用作预防和治疗血管疾病，肺部疾病，皮肤疾病，移植排斥，免疫性疾病和炎症状况的药物。
• Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
  申请人：——

  公开号：US20040254151A1

  公开（公告）日：2004-12-16

  The present invention pertains to certain alkane diol derivatives (including, e.g., mono- and di-esters) of the formula R 1 —O-A-O—R 2 , wherein: A is a C 2-10 alkylene group; R 1 is independently a first hydroxy protecting group (e.g., an ester group); and, R 2 is independently —H or a second hydroxy protecting group (e.g., an ester group); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrug thereof, which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or conditions associated with inflammation or activation of the immune system.

  本发明涉及某些烷基二醇衍生物（包括例如单酯和双酯），其化学式为R1-O-A-O-R2，其中：A是C2-10烷基链；R1是独立的第一羟基保护基（例如酯基）；R2是独立的-H或第二羟基保护基（例如酯基）；以及其医药上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药等，其中，它们可以抑制破骨细胞的存活、形成和/或活性；并且/或抑制骨吸收。本发明还涉及包含这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是体内还是体外，以抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导或以骨吸收为特征的疾病，例如骨质疏松症、类风湿性关节炎、与癌症相关的骨疾病、帕吉特病等，以及与炎症或免疫系统激活相关的疾病。
• POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS
  申请人：MERCK PATENT GMBH

  公开号：US20140375943A1

  公开（公告）日：2014-12-25

  The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerizable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the PSA (“polymer sustained alignment”) type.

  本发明涉及可聚合化合物、其制备过程和中间体、包含它们的液晶（LC）介质，以及将可聚合化合物和LC介质用于光学、电光和电子目的的使用，特别是在LC显示器中，特别是在PSA（“聚合物持续定向”）类型的LC显示器中。
• Instant adhesive composition
  申请人：LOCTITE CORPORATION

  公开号：EP0142327A1

  公开（公告）日：1985-05-22

  Cyanoacrylate adhesive compositions which employ silacrown compunds as additives given substantially reduced fixture and cure times on de-activating substrates such as wood. The silacrown compounds are preferably employed at levels of about 0.1-5% by weight of the composition.

  采用硅胶冠化合物作为添加剂的氰基丙烯酸酯粘合剂组合物，可大大缩短在木材等失活基材上的固定和固化时间。硅胶冠化合物的用量最好为组合物重量的 0.1-5%。